<DOC>
	<DOC>NCT00434733</DOC>
	<brief_summary>This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.</brief_summary>
	<brief_title>Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Subjects 18 years of age who signed the informed consent Receipt of another investigational agent within 4 weeks Receipt of influenza vaccination for current season 2006/2007. any acute disease or infection, history of neurological symptoms or signs, known or suspected impairment of immune function, any serious disease, bleeding diathesis fever (defined as axillary temperature ³38.0°C) within 3 days (prior to Visit 1) Pregnant or breastfeeding or females of childbearing potential who refuse to use an acceptable method of birth control Surgery planned during the study period Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination History of (or current) drug or alcohol abuse Any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Influenza H5N1, pandemic</keyword>
</DOC>